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Abstract
Background. Chronic Myeloid Leukemia (CML) is a myeloproliperative malignancy that is caused by 
reciprocal translocation between chromosomes 9 and 22 which form the BCR-ABL fusion gene. Most 
CML patients have a major type of BCR-ABL mutation. There are b3a2 and b2a2 types, which produce 
different oncoproteins in 25 amino acid elements. The expression of different proteins is thought to cause 
differences in clinical manifestations, laboratory, and prognosis. In CML, there are several prognostic scoring 
systems, including Sokal, Hasford, and EUTOS scores which combine clinical and laboratory parameters. 
The effect of this genomic breakpoint location on clinical and biological characteristics is still controversial.
Aims. The aim of this study was to determine the comparison of prognostic scores between CML patients 
with b3a2 and b2a2 BCR-ABL mutation types in Dr. Sardjito General Hospital.
Methods. This study was a cross sectional retrospective study used secondary data from medical records of 
Dr. Sardjito General Hospital, from March 2014 to April 2016. The prognostic score of Sokal, Hasford, 
and EUTOS was calculated in the BCR-ABL mutation type groups b3a2 and b2a2. Data were analyzed 
by Chi Square test.
Results. A total of 113 CML patients were analyzed with 74 (65.5%) b3a2 mutation type groups and 39 
(34.5%) b2a2 mutation type groups. Hemoglobin levels, leukocytes, platelets, basophils, and eosinophils 
did not differ significantly between the two groups of mutation types. Meanwhile, the statistical test for 
the phase of disease when the patient was first diagnosed in both types of mutations showed a significant 
difference (p = 0.005). More patients with types of b2a2 mutations came in the acceleration and blast crisis 
phases than b3a2 types. However, Sokal, Hasford, and EUTOS prognostic scores in the b3a2 mutation type 
group were not significantly different from the b2a2 group (p> 0.05).
Conclusions. There was no significant difference in prognostic scores of CML patients with the b3a2 BCR-
ABL mutation type compared with the b2a2 mutation type in Dr. Sardjito General Hospital Yogyakarta.
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Abstrak
Latar Belakang. Chronic Myeloid Leukemia (CML) merupakan kelainan keganasan mieloproliperatif yang 
disebabkan oleh translokasi resiprokal antara kromosom 9 dan 22 yang membentuk gena fusi BCR-ABL. 
Sebagian besar penderita CML mempunyai tipe mutasi mayor BCR-ABL yaitu jenis b3a2 dan b2a2, yang 
menghasilkan oncoprotein yang berbeda pada 25 elemen asam aminonya. Ekspresi protein yang berbeda diduga 
menyebabkan perbedaan manifestasi klinis, laboratoris, dan akhirnya prognosis. Pada CML dikenal beberapa 
sistem skoring prognostik, diantaranya skor Sokal, Hasford, dan EUTOS yang menggabungkan parameter klinis 
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Introduction
Chronic Myeloid Leukemia (CML) is a 
myeloproliperative malignancy that caused by 
reciprocal translocation between chromosomes 
9 and 22 which forms the BCR-ABL fusion 
gene and produces the protein tyrosine kinase 
that results in uncontrolled proliferation of 
myeloid cells.1 The BCR-ABL fusion gene 
can occur due to the breakpoints at three 
points, there are major BCR (M-BCR), minor 
(m-BCR) and micro (μ-BCR). Based on 
the 3 types of grouping, there are 7 types of 
breakpoint types in the BCR-ABL fusion gene, 
there are major b3a2, major b2a2, minor e1a2, 
micro e19a2, rare type e1a3, rare type e13a3 
and rare type e12a1.2 Each breakpoint type 
encodes a different type of protein and has a 
different leukemogenic activity, especially in 
the activity of the tyrosine kinase enzyme. The 
expression of different proteins causes different 
clinical manifestations and prognosis.3 
Clinical classification of CML is used 
today to assess prognostic factors. The scoring 
system prognostic of CML used Sokal, Hasford, 
and EUTOS scores which in principle combine 
clinical and laboratory factors. These three 
prognostic scores generally classify patients into 
low risk and intermediate-high risk groups.4 
In the majority of CML patients with 
positive BCR-ABL, about 95% of patients have 
b3a2 (e14a2) or b2a2 (e13a2) fusion gene. Both 
of b3a2 and b2a2 fusion genes encode P210 
kDa protein, which is only distinguished by 25 
amino acids encoded by exon b3. The effect of 
this genomic breakpoint location on clinical, 
laboratory, and prognostic characteristics is 
still controversial.5 Therefore, the authors were 
interested in analyzing the comparison of 
prognostic scores (Sokal, Hasford, andUTOS 
scores) between CML patients with b3a2 and 
b2a2 BCR-ABL mutation types in RSUP dr. 
Sardjito.
Methods
This study used a retrospective cross-
sectional design to determine the comparison 
of prognostic scores between CML patients 
dan laboratorium. Pengaruh lokasi breakpoint genomik ini terhadap karakteristik klinis dan biologis ini masih 
kontroversial.
Tujuan. Penelitian ini bertujuan untuk mengetahui perbandingan skor-skor prognostik antara pasien-pasien 
CML dengan tipe mutasi BCR-ABL b3a2 dan b2a2 di RSUP dr. Sardjito.
Metode. Penelitian ini merupakan penelitian cross sectional retrospective dengan menggunakan data sekunder 
pemeriksaan klinis dan hasil laboratorium dari rekam medik RSUP dr. Sardjito pada periode Maret 2014-April 
2016. Dilakukan perhitungan skor prognostik Sokal, Hasford, dan EUTOS score pada kelompok tipe mutasi 
BCR-ABL b3a2 dan b2a2. Uji statistik yang digunakan adalah uji Chi Square. 
Hasil Penelitian. Sebanyak 113 pasien CML dianalisis, dengan kelompok tipe mutasi b3a2 sebanyak 74 (65,5%) 
pasien dan b2a2 sebanyak 39 (34,5%) pasien. Kadar Hb, angka leukosit, trombosit, basofil, dan eosinofil tidak 
berbeda bermakna antara kedua kelompok tipe mutasi. Sedangkan, uji statistik untuk fase penyakit CML saat 
pertama kali pasien terdiagnosa pada kedua tipe mutasi menunjukkan adanya perbedaan bermakna (p= 0,005). 
Tipe mutasi b2a2 lebih banyak yang datang pada fase akselerasi dan krisis blast dibanding tipe b3a2. Namun, 
skor prognostik Sokal, Hasford, dan EUTOS pada kelompok jenis mutasi b3a2 tidak berbeda bermakna dengan 
kelompok b2a2 (p>0,05). 
Kesimpulan. Tidak terdapat perbedaan yang bermakna pada beberapa skor prognostik pasien CML dengan tipe 
mutasi BCR-ABL b3a2 dibanding tipe mutasi b2a2 di RSUP Dr. Sardjito Yogyakarta.
Kata kunci: Chronic Myeloid Leukemia (CML), tipe mutasi BCR-ABL, skor prognostik
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who have BCR-ABL  mutation type b3a2 with 
b2a2 mutation type in Dr. Sardjito General 
Hospital. The affordable population of the 
study were CML patients in the outpatient and 
inpatient installation at the Dr. Sardjito General 
Hospital in the period March 2014-April 2016. 
The sample of the study were newly diagnosed 
CML patients, aged > 18 years, with BCR-
ABL mutation types was b3a2 or b2a2, had 
not received any therapy, and had completed 
the medical record data. Exclusion criteria in 
this study were CML patients who had other 
comorbid diseases, there were chronic kidney 
disease, diabetes mellitus, chronic liver disease, 
infections and other malignancies.
Differences between the mean values of 
the numerical data b3a2 BCR-ABL  mutation 
type group and the b2a2 group were analyzed 
using the unpaired T test or the Mann-Whitney 
U test. For differences of Sokal, Hasford, and 
EUTOS scores, there were the low risk group 
and the intermediate-high risk group in the 
b3a2 BCR-ABL mutation type with the b2a2 
type were analyzed using the Chi Square test or 
Fisher’s exact test, with P value was significant 
if less than 0.05 (95% confidence interval).
Results
The flow of research shown in Figure 1. 
Basic characteristics data include age of first 
visit, sex, type of BCR-ABL mutation, phase 
of CML disease, hemoglobin level, leukocyte 
count, platelet count, basophil percentage, 
eosinophil percentage, blast cell count, and 
spleen size in cm, are explained in table 1.
The results of this study showed that 74 
(65.5%) CML patients had b3a2 mutation 
type, while the b2a2 mutation type were 39 
(34.5%) patients. In the data based on the 
BCR-ABL mutation type, subjects with the 
b3a2 mutation type had an average younger 
age of 42.0 ± 14.2 years compared to those of 
the b2a2 mutation type 46.7 ± 17.9 years, but 
were not significantly different (p = 0,132), as 
shown in table 2.
From the statistical analysis based on 
BCR-ABL mutation type, the phase of CML 
disease when the subject was first diagnosed, 
that showed significant difference between 
b3a2 and b2a2 types (p = 0,005). Blast cell 
count in CML patient with b3a2 mutation 
type compared to b2a2 type was significantly 
Figure 1. Flow of research subjects
Exclusion criteria :
Diabetes Mellitus = 8
Chronic Kidney Disease = 3
Hepatic cirrhosis = 1




Research subjects (n = 113)
CML patients who met the inclusion criteria
 (n = 132)
CML patients at Dr. Sardjito General Hospital for the period March 2014-April 2016 
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different (p = 0.036). However, the levels of 
hemoglobin, leukocytes, platelets, basophils 
and eosinophils are not different in the 
two types of mutations. Based on statistical 
analysis for the spleen size, there is a significant 
difference that splenomegaly in the b3a2 type 
is greater than b2a2 (p = 0.04).
The research subjects on b3a2 BCR-ABL 
mutation types group and b2a2 group, were 
grouping based on risk class of Sokal, Hasford, 
and EUTOS scores. The  statistical analysis used 
Chi square test as shown in table 3. In the three 
prognostic scores, the proportion of subjects 
included in the low risk group and intermediate-
high risk group in patients with b3a2 BCR-ABL 
mutation type compared to b2a2 mutation type 
showed no significant difference. 
Table 1. Basic characteristics of the research subjects (113 subjects)
Parameter n % Mean SD Med Min Max
Age (year) 43.6 15.7 44 18 80










Blast crisis 5 4.4
Hemoglobin (g/dl) 9.6 2.5 9.2 5.0 21
Leukocytes ( x103/mm3) 197.3 169.4 155 4.4 741.7
Platelets ( x103/mm3) 586.3 503 474 28 3368
Basophils (%) 2.6 3.1 1.3 0 12,3
Eosinophils (%) 2.9 2.7 2.3 0 12
Blast (%) 5.6 10.6 3 0 85
Spleen size (cm) from below left costal margin 15.1 7.3 16 0 32
Table 2. Basic characteristicsof the research subjects based on the type of BCR-ABL 
mutation
 Variable
Mean ± SD 
Median (Min - Max) P
b3a2 b2a2
Age (year) 42.0 ±14.2 46.7± 17.9 0.132*
Sex Male n (%) 48 (64.9) 19 (48.7) 0.144**
Female  n (%) 26 (35.1) 20 (51.3)
Phase of 
disease
Chronic n (%) 70 (94.6) 30 (76.9) 0.005***
Acceleration n (%) 3 (4.1) 5 (12.8)
Blast crisis n (%) 1 (1.4) 4 (10.3)
Hemoglobin (g/dl) 9.7 ± 2.6 9.2 ± 2.3 0.365*
Leukocytes ( x103/mm3) 161 (4.6-741.7) 146.4 (4.4-602.5) 0.833***
Platelets ( x103/mm3) 606 ± 560.9 548 ± 375.8 0.612*
Basophils (%) 2.1 ± 2.5 3.6  ± 3.9 0.381*
Eosinophils (%) 2.8 (0-12) 2.2 (0-12) 0.493***
Blast (%) 3 (0-30) 3 (1-85) 0.036***
Spleen size (cm) from below left costal margin 16(0-32) 16(0-32) 0.04***
* Unpaired T test , ** Chi square, ***Mann-Whitney U test, Significance : P < 0.05
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Discussion
In this study, the number of subjects with 
b3a2 BCR-ABL mutation type is higher than 
b2a2 mutation type, which is 65.5% compared 
to 34.5%. The results are different from the 
research of Deb et al. in India which had 56.25% 
subjects with b3a2 mutation type, 41.25% b2a2 
mutation type and 2.5% other types.6 The study 
of Jain et al. also found different results, there were 
41% b3a2 mutation type, 42% b2a2 type, and 
18% both of b3a2 and b2a2 type.7 In the study 
of Luke et al. obtained 55% subjects with b3a2 
mutation type and 45% b2a2 type.8 Subjects 
with b2a2 mutation type in this study more 
to be excluded because they came with other 
comorbid diseases, for example infections due 
to clinical conditions which initially were worse 
than the b3a2 mutation type. This causes the 
comparison of the number of mutations in this 
study is different from other studies.
The age of the CML patients when first 
diagnosed for the b2a2 mutation type was 46.7 
years, that was older than the b3a2 mutation 
type which was 42 years, but it was not 
statistically significant different (p = 0.132). 
These results are similar to the study of Jain 
et al. and De Almeida Filho et al.7,9, which 
described that patients with CML with the 
mutation types b3a2 and b2a2 does not mean 
any different. However, in a study in India by 
Deb et al in 2014 was found that the age of 
patients with CML type B2A2 mutation was 
older and significantly different.
In this study, the hemoglobin level of 
the subjects with b2a2 mutation type, was 
lower at 9.2 g/dl compared to the subjects 
with b3a2 type which was 9.7 g/dl, but it 
was not statistically significant (p = 0.365). 
Leukocytes count of subjects with b3a2 
mutation type is almost similar to subjects with 
b2a2 mutation type (p = 0.833). The platelet 
count in subjects with b3a2 type was slightly 
higher (mean = 606x103/mm3) compared to 
the b2a2 mutation type (mean = 548x103/
mm3), but  it was not statistically significant 
(p = 0.612). The hematological profile of the 
subjects in this study is similar to the results of 
Bazatlenko et al. study which showed that was 
no significant difference between hemoglobin 
levels, leukocytes count and platelets count in 
CML patients with  b3a2 BCL-ABL transcript 
compared to b2a2. However, different things 
were found in the study of Vasconcelos et 
al. which showed that the b3a2  BCR-ABL 
transcript is associated with a higher platelet 
count (thrombocytosis), whereas the b2a2 
transcript shows a higher leukocyte count.10,11
Based on the phase of CML disease, 
it was found that the b2a2 mutation type 
group was more in the acceleration and blast 
Table 3. Comparison of Sokal, Hasford, and EUTOS scores on b3a2 and b2a2 
BCR-ABL mutation types.






Low risk 3 (4.1%) 2 (5.1%) 0.566*
Intermediate - High risk 71 (95.9%) 37 (94.9%)
Hasford score
n (%)
Low risk 6 (8.1%) 4 (10.3%) 0.471*
Intermediate - High risk 68 (91.9%) 35 (89.7%)
EUTOS score
n (%)
Low  risk 42 (56.8%) 25 (64.1%) 0.579**
High risk 32 (43.2%) 14 (35.9)
* Fisher, **Chi square, Significance : P < 0.05
Acta Interna The Journal of Internal Medicine, Volume 10, Number 1, June 2020: 22-28
27 
crisis phase compared to the b3a2 mutation 
type, and this was significantly different (p = 
0.005). These results are similar to the study 
of Polampalli et al. at India with 202 research 
subjects.12 However, the different results were 
obtained in Vanconceles et al. study at Brazil.11
The percentage of blast cells in b2a2 
mutation type was also higher compared to 
b3a2 mutation type and it was significantly 
different (p = 0.036). This is certainly related 
to the number of patients who come in 
acceleration and blast crisis phases, which is 
more commonly found in b2a2 mutation type 
compared to b3a2 type. It also shows a higher 
leukemogenic activity in the b2a2 mutation 
type.
Based on BCR-ABL mutation type, 
basic characteristics of subjects showed that 
subjects with the b2a2 mutation type had a 
clinical profile that tended to be worse than 
the b3a2 mutation type, as evidenced by the 
CML disease phase when the patient was first 
diagnosed and blast cell counts.
On the spleen palpation, the same 
median was obtained between the type of 
mutation b3a2 and b2a2 which is 16 cm. 
However, after statistical analysis, there were 
significant differences in the types of b3a2 and 
b2a2 (p = 0.04). The type of b3a2 mutation 
had a greater spleen than b2a2 type. This result 
might because the number of b3a2 mutations 
is higher and the average CML patients who 
come to RSUP dr. Sardjito tends to be late, 
with most of their main complaints being an 
enlarged abdomen, due to splenomegaly.
In this study, from the calculation of 
Sokal, Hasford, and EUTOS prognostic scores 
showed results that did not differ significantly 
between the b3a2 and b2a2 types of BCR-
ABL mutations. These results are same as the 
study of De Almaida et al. at Brazil which 
also compared the three prognostic scores in 
both of types of mutations.9 However, Deb 
et al. at India showed CML patients with 
b2a2 BCR-ABL  transcripts type had higher 
Sokal, Hasford and European Treatment and 
Outcomes Study scores than b3a2 transcripts 
type, or worse prognostic scores.6 The results 
of researchs regarding the relationship of 
BCR-ABL mutation types with prognostic 
score of CML patients is still varied, so it is 
still controversial.
The absence of differences between the 
haematological, clinical profile and prognostic 
score in CML patients with b3a2 and b2a2 
mutation types is the number of samples with 
b2a2 mutation type fewer than b3a2 type. 
In this study, CML patients with the b2a2 
mutation type were more excluded because 
they came with other comorbidities, such as an 
infection that might be related to the clinical 
condition or phase of the disease when the 
patient arrived. In addition, differences in the 
spleen size between both of mutation types, the 
results obtained that the type b3a2 has a larger 
spleen size, which will affect the calculation of 
prognostic scores.
Conclusion
There was no significant difference in 
prognostic scores of CML patients with the 
b3a2 BCR-ABL mutation type compared with 
the b2a2 mutation type in Dr. Sardjito General 
Yogyakarta.
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